M&A Advisory in Indiana
Indiana ranks #1 in the U.S. for manufacturing GDP per capita and hosts the Orthopedic Capital of the World in Warsaw — home to ~⅓ of global orthopedic device output — while Eli Lilly's $50B+ committed life sciences investment since 2020 anchors the state's highest-multiple M&A engine.
Indiana's M&A Economy
Indiana's lower middle market M&A is structurally one of the most active in the Midwest on a per-capita basis. The state's GDP reached ~$545B in 2025 (17th nationally), with real GDP growing 2.6% YoY — outpacing all four bordering states (IL +1.3%, OH +1.4%, MI +0.4%, KY +0.9%) and the 2.1% national average. Manufacturing contributes ~$114.6B, roughly 27% of state GDP, making Indiana #1 in the U.S. for manufacturing as a share of GDP. Indiana led the nation in pharmaceutical and medicine exports at $22.4B in 2024, anchored by Eli Lilly's LEAP Innovation District in Lebanon ($9B API site), Catalent, Baxter, Roche Diagnostics, and Cook Medical. The Warsaw orthopedic cluster (Zimmer Biomet, DePuy Synthes, Medtronic Spine) produces roughly one-third of the global $38B orthopedic device market. Elkhart-South Bend produces ~80% of U.S. RVs — Thor Industries, Forest River, Lippert, Patrick Industries — creating a perennial PE roll-up target base. Northwest Indiana is the largest single steel-producing region in the U.S. The state's 4.9% flat corporate income tax (lowest in the Midwest), no inventory or gross-receipts tax, no estate tax, individual rate falling to 2.95% in 2026, and #10 ranking on the Tax Foundation 2026 State Tax Competitiveness Index create an environment where buyer EBITDA quality narratives translate directly into 0.25x–0.75x multiple expansion versus comparable assets in Illinois, Minnesota, or Michigan. Indianapolis is a maturing secondary PE hub — Hammond Kennedy Whitney, Centerfield Capital, Cardinal Equity, Monument MicroCap, CID Capital, and Periculum Capital are all actively deploying with ≤3-hour proximity to Chicago capital markets.
Indiana at a Glance
Key Markets in Indiana
Indianapolis–Carmel–Anderson MSA
Indiana's dominant deal hub with a population of ~2.1M and the headquarters of Eli Lilly, Allison Transmission, Cummins, Anthem/Elevance, and Rolls-Royce North American defense. Carmel and Fishers are growing fintech/SaaS hubs. Home to virtually every Indiana-based PE firm: HKW, Centerfield, Cardinal Equity, Monument MicroCap, CID Capital, and Periculum Capital. Within 3 hours of Chicago capital markets.
Fort Wayne MSA
Indiana's second-largest industrial economy (pop. ~430K) with a deep diversified supplier base. Headquarters of Do It Best, Franklin Electric, and Steel Dynamics. GM Fort Wayne Assembly produces the Silverado and Sierra. Strong defense electronics and building products clusters create steady LMM deal flow independent of automotive cycles. The Fort Wayne market draws buyers from both Indianapolis and Chicago PE communities.
South Bend–Elkhart–Mishawaka
The "RV Capital of the World" with a combined population of ~810K and one of the most acquisition-active manufacturing micro-clusters in the country. THOR Industries and Forest River are headquartered here alongside major suppliers Lippert Components and Patrick Industries. Notre Dame anchors a growing tech and biotech research base that is beginning to feed an early-stage venture-to-M&A pipeline.
Evansville MSA
A tri-state regional hub (IN/IL/KY, pop. ~315K) and headquarters of Berry Global ($12B revenue, major PE consolidator in plastics/packaging), Mead Johnson Nutrition, and Old National Bancorp. Toyota Manufacturing Indiana operates in nearby Princeton. Evansville's position at the convergence of three states draws buyers from Louisville, Nashville, and St. Louis as well as Indianapolis, producing competitive auction dynamics for quality assets.
How Does Indiana Compare?
Indiana M&A benchmarks vs. neighboring states.
Indiana Deal Landscape 2025–2026
Indiana middle-market M&A volume softened in H2 2024 as elevated rates and election uncertainty pushed sellers to a wait-and-see mode. Post-election optimism drove a pent-up rebound into early 2025, partially blunted by tariff uncertainty by mid-2025. By early 2026, deal flow was reportedly back at multi-year highs — Periculum Capital noted handling six deals in two months in early 2026, equal to a typical full year. Private equity is the dominant acquirer class statewide, particularly for accounting firms, residential services (HVAC/plumbing), and lower-middle-market industrial platforms, while strategic acquirers dominate headline-grabbing deals in orthopedics, pharma, RVs, and steel. The single biggest M&A driver is the Eli Lilly-led pharmaceutical capacity buildout, which has unlocked >$50B of investment and a CDMO/logistics roll-up wave.
Warsaw Orthopedic Strategic Roll-Up Acceleration
Zimmer Biomet has pursued an aggressive bolt-on strategy: $1.2B Paragon 28 (foot/ankle, April 2025), Monogram Technologies (AI robotics, October 2025), and OrthoGrid Systems (Q4 2024). Switzerland's Medartis acquired Warsaw-based Nextremity Solutions for up to $70M. Highridge Medical divested its EBI Bone Healing business in June 2025. The cluster is seeing 8–12 announced ortho transactions per year, with strategic acquirers paying premiums for AI/robotics IP. Pediatric specialist OrthoPediatrics continues add-on activity.
Pharma CDMO and Fill-Finish Capacity Land Grab
The Lilly-tirzepatide demand wave is reshaping Indiana's CDMO landscape. Novo Holdings' $16.5B Catalent acquisition put the Bloomington fill-finish site in Novo Nordisk's hands. Lilly acquired the Nexus Pharmaceuticals injectable plant and Morphic Holding (immunology). INCOG BioPharma is investing $200M in Fishers with 1,000 jobs by 2030. Indianapolis-based investment banks Periculum Capital and Stout are active advisors; PE platforms targeting ancillary life-sciences services are scouting Indiana aggressively.
PE Roll-Ups in Residential Services, Accounting, and Niche Distribution
HKW (Indianapolis, HKW V $365M fund) focuses on $5–30M EBITDA manufacturing, distribution, and business services platforms; recent activity includes Handling Systems & Conveyors (February 2026) and AliMed recap (August 2025). Centerfield Capital Partners ($400M Fund V) invested in ALM Positioners (April 2025) and Regency Electric (October 2025). Indianapolis residential plumber Hope Plumbing was recapitalized by Redwood Services. Central-Indiana accounting firm M&A reached an "unprecedented pace" per Barnes & Thornburg with Renovus Capital-style PE platforms acquiring CPA firms.
Strategic Carve-Outs and Cross-Border Industrial Consolidation
Indiana's anchor strategics are reshaping portfolios. Cummins completed the Atmus Filtration spin-off in March 2024 ($1.3B gain). In Northwest Indiana, Cleveland-Cliffs acquired Stelco ($2.5B, November 2024) and is negotiating to acquire NLMK's Portage, IN EAF mill, while Nippon Steel completed its $14.9B acquisition of U.S. Steel, affecting Gary Works. Elkhart RV consolidation continues with Thor's Heartland-into-Jayco realignment. German strategic Jungheinrich's ~$375M Storage Solutions purchase and DHL's IDS Fulfillment deal underscore foreign strategics' interest in Indiana's logistics base.
Exit Preparation Timeline
A practical roadmap for Indiana business owners planning an exit.
- Conduct an entity and QSBS check-up — confirming C-corp QSBS eligibility (Section 1202 5-year clock, $50M/$75M gross-asset cap, qualified trade) for Indianapolis/Bloomington/Warsaw founders; for S-corps and LLCs, model F-reorg or QSub options ahead of OBBBA's expanded exclusion.
- Initiate the annual Indiana Pass-Through Entity Tax election under IC 6-3-2.1 by the entity return due date to capture the federal SALT deduction at 3.00%/2.95% — a permanent tax savings at the entity level, not a deferral.
- Execute county Local Income Tax (LIT) residency planning by documenting principal-residence county across all 92 Indiana counties and considering relocating closing-year domicile from a 2.0%+ LIT county (Marion at 2.02%) to a sub-1.0% county to reduce Indiana-source tax on the gain.
- Implement a pre-transaction estate freeze leveraging Indiana's zero state estate and inheritance tax (repealed by HEA 1001/2013) to push minority interests into GRATs and IDGTs at pre-LOI valuation discounts; only federal estate/gift tax (40% top rate, $13.99M individual exemption in 2025) applies.
- Conduct an Indiana sales/use tax exposure scrub — reconciling 7% IN statewide sales tax on any historical taxable sales, especially manufacturers selling outside the machinery/equipment (M&E) exemption; a clean trail dramatically reduces successor-liability haircuts under IC 6-8.1-10-9.5.
- Optimize apportionment to leverage Indiana's no-throwback rule (SB 441/2015, single sales factor): re-paper sales contracts and shipping flows to maximize "nowhere income" excluded from the IN sales factor numerator and not taxed by the destination state — one of the most underutilized planning levers in Midwest M&A.
- Complete an R&D credit and EDGE/Hoosier Business Investment (HBIC) credit study — these credits stack generously with federal §41 and add directly to EBITDA in a Quality of Earnings, with Big 4 and regional firms (Katz Sapper Miller, Crowe, Plante Moran, Forvis) engaged for QofE preparation.
- For Warsaw orthopedic and Indianapolis pharma/CDMO sellers, initiate FDA regulatory preparation: if management is the named "Management Representative" on the QMS, transition three OEM relationships to a newly hired VP of Sales over 12 months to de-risk key-person concentration before launch.
- Build asset vs. stock structure modeling — at Indiana's flat ~3% combined rate, the typical seller gross-up demanded for asset deals is lower than in high-tax states, often unlocking deal structures unavailable elsewhere; model §338(h)(10) elections and F-reorganization scenarios.
- Execute bulk-sale notice planning by pre-drafting Indiana DOR Form 57309 and identifying the 45-day pre-close filing trigger under IC 6-8.1-10-9.5 (effective for transfers after February 14, 2024) — the form applies to both asset and equity sales exceeding 50% of tangible personal property by value.
- Run buyer universe targeting to Indiana-cluster strategics (Eli Lilly orbit pharma in Indianapolis; Zimmer Biomet/DePuy Synthes/Medtronic in Warsaw; Thor/Forest River/Winnebago in Elkhart; Cummins/Allison in Columbus/Indianapolis) plus Midwest middle-market PE; bind reps and warranty insurance (2.5–4.0% of policy limit — Indiana's clean tax environment produces lower underwriting friction).
- File Phase I ESA under ASTM E1527-21 for all owned/leased facilities; for IDEM-regulated properties, check the Institutional Controls Registry for Environmental Restrictive Covenants (ERCs) under Indiana Code §13-25-3 (IRPTL) — ERCs run with the land and termination requires reimbursing IDEM at $75/hour staff time per 329 IAC 1-2-7.
- File Indiana DOR Form 57309 bulk transfer notice at least 45 days pre-close to obtain the DOR clearance letter (typically 20-day turn) and extinguish successor liability under IC 6-8.1-10-9.5 — initiating at LOI is best practice given the critical-path timing.
- Execute the final-year Indiana PTE Tax election under IC 6-3-2.1 — for S-corp/LLC sellers, the year-of-sale election captures the federal deduction on the gain at the entity level at 3.00% (2025) / 2.95% (2026) flat rate; missing the election deadline (original or extended entity return due date) is unrecoverable and can cost $250K+ in permanent federal tax savings on $25M+ deals.
- File Form BC-100 (Business Tax Closure Request) via INTIME at asset-sale closing to close Indiana sales, withholding, and Financial Institutions Tax accounts; pair with IT-966 for entity dissolution and allow 2–4 weeks of post-close administrative processing.
- Allocate purchase price under §1060 with Indiana apportionment in mind — across goodwill (favorable apportionment treatment under no-throwback rule), tangible assets (7% sales tax exposure), and IP (often "nowhere income"); implement post-close residency, charitable, and Opportunity Zone planning across Indiana OZ designations in Indianapolis, Gary, South Bend, and Evansville.
Why Indiana Business Owners Choose Ad Astra
Local market knowledge and national buyer networks — the combination that drives premium outcomes for Indiana business owners.
Schedule a ConsultationWarsaw & Indianapolis Cluster Expertise
We have closed transactions across Indiana's three defining clusters: Warsaw orthopedics (the Zimmer Biomet/DePuy Synthes/Paragon/OrthoPediatrics ecosystem accounting for ~33% of global orthopedic devices), Indianapolis pharma and life sciences (Eli Lilly headquarters and surrounding CDMO/CRO supply chain — Indiana ranks #1 nationally in pharmaceutical manufacturing output), and the Elkhart–South Bend RV/specialty vehicle corridor (Thor Industries, Forest River, Winnebago — ~80% of U.S. RV production). Vertical-specific buyer maps and comparable-transaction databases are built in-house.
Indiana Tax Structure Mastery
Indiana's flat 3.00% (2025) / 2.95% (2026) individual rate trajectory toward 2.90% in 2027 creates a real, quantifiable after-tax advantage over Illinois (4.95%), Michigan (4.25%), and Ohio peers. We optimize the IC 6-3-2.1 Pass-Through Entity Tax election in the year of sale — for pass-through sellers, the entity-level federal deduction at a 3.00% rate produced $250K+ of permanent federal tax savings on recent transactions. We also navigate the IC 6-8.1-10-9.5 bulk-sale notice procedure (Form 57309, 45-day pre-close filing trigger) and county Local Income Tax optimization across all 92 Indiana counties.
Strategic and Financial Buyer Relationships
Active dialogue with Indianapolis (Eli Lilly, Roche Diagnostics, Elanco, Catalent), Warsaw (Zimmer Biomet, Medtronic Spine & Biologics, Stryker), and Elkhart (Thor, Forest River, Patrick Industries, LCI) corporate development teams, plus middle-market PE platforms with Indiana-resident operating partners: HKW ($365M Capital Partners V), Centerfield Capital ($400M Fund V), CID Capital, Monument MicroCap, and Cardinal Equity Partners. These relationships produce competitive auction processes that out-of-state advisors without Indiana operating presence cannot replicate.
Indiana Regulatory and Labor Environment
Indiana's right-to-work statute under IC 22-6-6 (enacted 2012) supports labor cost predictability and non-unionized workforces that translate into cleaner buyer underwriting. We navigate FDA/ISO regulatory environments unique to Indianapolis and Warsaw life-sciences clusters — FDA 21 CFR 820, ISO 13485 cGMP — alongside EDGE/Hoosier Business Investment credit studies that stack generously with federal §41 R&D credits and add directly to EBITDA in a QofE. Indiana's no-throwback rule on single sales factor apportionment creates "nowhere income" excluded from the IN numerator — a persistent and underutilized planning lever for in-state manufacturers selling out of state.
Indiana M&A Activity Highlights
Eli Lilly announced a $27B four-site U.S. expansion in February 2025 plus a $5.3B incremental commitment to Lebanon, IN raising the LEAP campus to $9B; total post-2020 U.S. manufacturing commitments exceed $50B, anchoring CDMO/logistics M&A for years.
Zimmer Biomet completed the $1.2B Paragon 28 acquisition (April 2025) and Monogram Technologies acquisition (October 2025), expanding into foot/ankle and AI-driven autonomous robotics from Warsaw HQ.
Novo Holdings' $16.5B Catalent acquisition (closed late 2024) transferred the Bloomington, IN fill-finish complex to Novo Nordisk — the largest pharma services M&A transaction touching Indiana in 2024.
DHL Supply Chain acquired Plainfield, IN-based IDS Fulfillment (May 2025, +1.3M sq ft); Calera Capital-backed FitzMark acquired Hometown Logistics (September 2025); Jungheinrich AG acquired Storage Solutions for ~$375M — illustrating the depth of Indiana logistics M&A.
Nippon Steel closed its $14.9B acquisition of U.S. Steel affecting Gary Works (2025), while Cleveland-Cliffs acquired Stelco for $2.5B (November 2024) and is negotiating to acquire NLMK's Portage, IN EAF mill — reshaping NW Indiana's steel landscape.
Tax & Deal Structure in Indiana
Indiana presents one of the most seller-friendly tax environments in the Midwest. The flat individual rate is on a legislatively guaranteed downward glidepath — 3.00% in 2025, 2.95% in 2026, 2.90% in 2027 per HEA 1001/2023 and HEA 1002. There is no state estate or inheritance tax, the 4.9% corporate rate is among the lowest nationally, and Indiana repealed its throwback rule effective after 2015. Combined with single sales factor apportionment and right-to-work status under IC 22-6-6, Indiana is structurally favorable for shareholders monetizing privately held businesses across every sector.
Indiana Individual Income Tax & PTE Election
FavorableFlat individual AGI tax of 3.00% (2025), 2.95% (2026), and 2.90% (2027). The Indiana Pass-Through Entity Tax under IC 6-3-2.1 (enacted SB 2/2023, retroactive to 2022) is a SALT-cap workaround whose rate equals the applicable individual rate; the election is annual and irrevocable and must be made by the original or extended due date of the entity return (April 15/Nov. 17 extension). Sellers must also factor in county Local Income Taxes across all 92 counties at rates ranging from ~0.5% to ~3.0%; combined IN state + county effective rate generally falls in the 3.5%–6.0% range — materially below most Midwestern peers.
Capital Gains Treatment
FavorableIndiana taxes long-term capital gain on business sales at the same flat individual rate (3.00% in 2025, 2.95% in 2026), plus county LIT. The very low absolute rate makes Indiana's effective state capital gains burden the lowest among Midwestern peers with an income tax. On a $25M gain, the Indiana state-only differential versus Illinois is roughly $487K in the seller's favor. Indiana starts from federal AGI, so federal §1411 NIIT and federal LTCG rate (15%/20%) layer on top.
QSBS / Section 1202 Conformity
FavorableIndiana income tax begins with federal AGI (IC 6-3-1-3.5), so federally excluded Section 1202 QSBS gain is automatically excluded for Indiana purposes — Indiana has no decoupling provision adding back §1202 gain. Indiana uses static conformity to IRC as of January 1, 2023, meaning OBBBA's expanded QSBS provisions (post-July 4, 2025 stock) do not yet apply at the Indiana level until the 2026 General Assembly updates conformity. For qualifying C-corp founders on pre-OBBBA stock, the federal exclusion (greater of $10M or 10× basis) flows through, producing a true 0% combined federal + Indiana rate on excluded gain.
Bulk Transfer Notification (Form 57309)
NeutralIC 6-8.1-10-9.5 (effective for transfers after February 14, 2024) imposes a bulk transfer notification requirement: whenever a business transfers more than 50% of its tangible personal property by value — through either an asset OR equity sale — the parties must file Form 57309 with the Indiana DOR at least 45 days before closing or risk full successor liability for the seller's unpaid taxes (capped at the purchase price). The DOR issues a clearance letter within approximately 20 days. The 45-day clock is a critical-path item and should be initiated at LOI.
No Throwback Rule + 4.9% Corporate Rate
FavorableIndiana eliminated its sales-factor throwback rule effective for tax years beginning after December 31, 2015 (SB 441/2015) and uses single sales factor apportionment — so an Indiana-domiciled C-corp shipping product into states where it lacks nexus generates true "nowhere income" excluded from the IN numerator. Indiana's flat corporate AGI tax rate is 4.9% (since July 1, 2021), combined with no franchise/net-worth tax, right-to-work status (IC 22-6-6), and small-business personal property tax exemption under $80K. This cluster supports buyer EBITDA quality narratives translating into 0.25x–0.75x multiple expansion versus comparable assets in IL or MN.
No Estate or Inheritance Tax
FavorableIndiana repealed its inheritance tax retroactive to January 1, 2013 (signed May 8, 2013), and its pick-up estate tax was repealed by HEA 1001/2013. For 2025 and 2026, Indiana imposes no state-level estate, inheritance, or generation-skipping transfer tax, and no IH-6 returns are required. Sellers can execute GRATs, IDGTs, gifting of pre-liquidity-discounted minority equity to dynasty trusts without any state-level transfer tax drag — only federal estate/gift tax (40% top rate, $13.99M per individual in 2025) applies.
Representative Transaction
Illustrative model only. Not representative of a current or past Ad Astra Equity client engagement. Details modified to protect client confidentiality. Ranges are representative.
The Business
Warsaw, Indiana–based orthopedic component contract manufacturer supplying FDA-compliant titanium and cobalt-chrome implant components to Tier-1 OEMs in the Warsaw cluster
Key Metrics
Revenue
$38M–$46MAdjusted EBITDA
$7.5M–$9.5MMargin
~20–22% (above Warsaw cluster median)Quality
FDA 21 CFR 820 / ISO 13485; 3 consecutive clean Form 483-free inspections; <250 PPM defect rate; 98.4% on-time deliveryThe Challenge
Two compounding diligence risks required pre-market remediation. First, key-person concentration: the founding CEO (age 67) personally held the top three OEM relationships and was the named "Management Representative" on the QMS, creating both succession and FDA regulatory continuity risk. Second, a latent Indiana sales/use tax exposure on certain tooling purchases (~$180K aggregate) surfaced in QofE and required an IDOR voluntary disclosure under Indiana Code pre-close, creating timeline complexity in a market where Warsaw orthopedic talent competes against Zimmer Biomet, Paragon Medical, and OrthoPediatrics for the same CNC machinist and quality-engineer pool.
The Process
- 1Executed an 18-month sell-side preparation — sell-side QofE with Katz Sapper Miller, FDA mock audit, IDOR voluntary disclosure for the use-tax exposure (~$180K), and Indiana PTE Tax elections for tax years 2024 and 2025 under IC 6-3-2.1; founder transitioned three OEM relationships to a newly hired VP of Sales over 12 months.
- 2Ran a targeted, limited auction to 14 buyers (9 strategics including European entrants and 5 PE platforms with healthcare-manufacturing theses), emphasizing the FDA inspection record, ISO 13485 certification, and Warsaw cluster proximity advantages; generated 6 IOIs, advanced 4 to management presentations, and produced 2 final-round LOIs.
- 3Executed definitive agreement and Form 57309 bulk-transfer filing 50 days pre-close under IC 6-8.1-10-9.5, with DOR clearance letter received in 18 days; RWI bound at 3.1% of $12M limit.
- 4Structured as a stock sale with §338(h)(10) election to deliver buyer's desired step-up in basis while preserving seller's flat ~3.00% Indiana individual rate; final Indiana PTE Tax election captured $250K+ of permanent federal tax savings on the transaction-year gain.
- 5Coordinated post-close county LIT optimization — confirmed domicile in Hamilton County (1.10%) rather than Marion County (2.02%) saved $180K in county tax on the closing proceeds.
Deal Outcome
Enterprise Value
8.5x–10.0x TTM Adjusted EBITDA
Premium vs. Market
22%–28% above initial PE indications, driven by strategic synergy and clean FDA record
Time to Close
~9 months from CIM launch to close (LOI to close: 95 days)
Seller Rollover
~80% cash at close, 10% rollover equity into buyer parent, 10% earnout over 24 months tied to OEM-specific revenue retention; standard escrow plus RWI; founder consulting agreement (12 months) and 3-year non-compete
Key Lessons
- Initiate Indiana DOR Form 57309 early — even on stock deals it now applies under IC 6-8.1-10-9.5; the 45-day pre-close clock becomes a critical-path item that can delay funding if not started at LOI.
- Leverage the Indiana PTE Tax election (IC 6-3-2.1) in the year of sale — for pass-through sellers, the entity-level federal deduction at the 3.00% (2025)/2.95% (2026) flat rate produced $250K+ of permanent federal tax savings; missing the election deadline is unrecoverable.
- De-risk FDA key-person and QMS-personnel concentration at least 18 months pre-process — in Warsaw's orthopedic ecosystem, regulatory continuity (Management Representative, MDSAP-qualified personnel, clean Form 483 record) is as material to buyer underwriting as customer concentration, and buyers price the risk with a 1.0x–1.5x EBITDA discount absent visible succession.
- Voluntary disclosure of historical use-tax exposure before launch prevents buyer-driven price reductions mid-process — IDOR generally provides penalty relief on voluntary disclosures, and a clean tax trail dramatically reduces IC 6-8.1-10-9.5 successor-liability haircuts in due diligence.
Frequently Asked Questions
Common questions about selling a business in Indiana.
Still have questions? Let's talkAlso serving neighboring states
Ready to Explore Your Indiana Exit?
Schedule a confidential conversation to discuss your Indiana business, your goals, and how our local expertise and national buyer network can maximize your outcome.